Life Sciences
Navigate forward to interact with the calendar and select a date. Press the question mark key to get the keyboard shortcuts for changing dates.
Navigate backward to interact with the calendar and select a date. Press the question mark key to get the keyboard shortcuts for changing dates.
Innovation is essential to promoting human health, agricultural productivity, and ecological sustainability. ITIF’s Center for Life Sciences Innovation conducts research supporting advances in human biotechnology; pharmaceuticals; and health care policy outside the realm of IT.
Featured
More Publications and Events
May 15, 2024|Blogs
The “Invent Here, Make Here” Act Should Fully Advance, Not Partially Impede, Bayh-Dole’s Mission
The bill proposes useful steps to facilitate domestic commercialization, but it overreaches in placing excessive restrictions when innovators prove unable to identify domestic manufacturing capabilities despite their best efforts.
May 6, 2024|Reports & Briefings
The Relationship Between Biopharma R&D Investment and Expected Returns: Improving Evidence to Inform Policy
Better evidence is needed to evaluate the impact of policy changes on new drug development. Greater availability of government data should support more rigorous evaluations to inform evidence-based policymaking.
April 22, 2024|Reports & Briefings
LATAM Health Champions, 2024
Innovation plays a critical role in improving public health and in overcoming global health challenges. The call for LATAM Health Champions, which ran from February 5 to March 5, 2024, received more than 60 applications proposing innovative health solutions to a wide range of health challenges. Here, the top 20 are highlighted.
March 5, 2024|Events
Preserving U.S. Leadership in Biopharmaceutical Innovation
Watch now for an expert panel discussion surrounding the ITIF report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.
February 29, 2024|Reports & Briefings
Not Again: Why the United States Can’t Afford to Lose Its Biopharma Industry
America’s leadership in advanced-technology industries can never be taken for granted, as evidenced by its losses in telecommunications equipment, semiconductors, televisions, solar panels, and chemicals. Policymakers must recognize what went wrong in those cases to avoid a similar industrial decline in the biopharmaceutical industry.
February 12, 2024|Blogs
Fact of the Week: A 1 Percent Increase in Drug Prescriptions Can Reduce Spending on Other Medical Services by 0.2 Percent
A report from the Congressional Budget Office suggests that on average, a 1 percent increase in prescriptions was associated with a 0.2 percent decrease in spending on other medical services.
February 6, 2024|Testimonies & Filings
Comments to the NIST Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
America’s innovation system is fragile, and its leadership in advanced technology industries is never guaranteed or assured. The United States has taken—only to sacrifice—its lead in a wide-range of advanced technology industries, often in part because of significant policy lapses. It’s no time for additional unforced errors.
January 31, 2024|Testimonies & Filings
Comments to the U.S. Department of Health and Human Services Regarding the WHO Pandemic Preparedness Agreement
The United States should not endorse an IPR waiver in the WHO Pandemic Preparedness Agreement. It would not increase the number of vaccines or therapeutics, or the global supply that might be needed to address a future global pandemic.
December 11, 2023|Blogs
Biden’s Assertion of Excessive Biopharma Industry Concentration Is a Flawed Rationale for a Flawed Policy
The administration is flat wrong that America’s biopharmaceutical industry is excessively concentrated. It’s also flat wrong that U.S. drug prices are rising out of control.
November 13, 2023|Testimonies & Filings
Comments to the European Commission Regarding the EU General Pharmaceuticals Legislation
Changes proposed in the EU General Pharmaceutical Legislation would double down on policies that hinder, not enable, EU life-sciences innovation potential, while forsaking other avenues that could more effectively enhance access without compromising innovation.